The largest community of pharma leaders

PPD Named CIO 100 Award Winner for Clinical Research Data-Visualization Tool

WILMINGTON, N.C.–()–PPD, Inc. (Nasdaq:PPD) has been named by IDG’s CIO as a 2020 CIO 100 Awards honoree for deploying a data-visualization platform enabling PPD to more quickly visualize targeted patient populations and investigator sites conducting clinical trials for pharmaceutical and biotech customers, helping speed the development of life-changing medicines.

For more than 30 years, the CIO 100 Awards have recognized innovative organizations around the world that exemplify the highest level of operational and strategic excellence in information technology (IT).

PPD was honored for its Preclarus® site and patient visualization tool, which accesses multiple sources of data to create, in real-time, an interactive global map of potentially trial-eligible patients and investigator sites for clinical research programs in a wide variety of diseases and medical conditions.

“The Preclarus site and patient visualization tool provides an intuitive way to help our drug development customers rapidly identify the optimal locations for patient enrollment, which is key to delivering safe new drugs to improve health,” said Rob Petrie, senior vice president and chief technology officer at PPD. “This new technology allows PPD teams to more efficiently and effectively define our site and patient strategies for enrolling patients into a clinical trial and demonstrate to customers the rationale behind our data-driven approach, using detailed yet easy-to-understand maps and visuals.”

The annual CIO 100 Awards celebrate 100 organizations and their teams that are using IT in innovative ways to deliver business value.

“Today’s most successful companies are using IT to deliver business value, whether by enabling growth, optimizing business processes, or improving relationships with customers,” said Adam Dennison, senior vice president and general manager of IDG Events and publisher of CIO. “We are honored to showcase the technology innovation shown by this year’s CIO 100 winners and look forward to celebrating their accomplishments at the CIO 100 Symposium and Awards Ceremony.”

Executives from the winning companies will be recognized at the event Aug. 19 at the Terranea Resort in Rancho Palos Verdes, California.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 24,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppdi.com.

This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest Annual Report on Form 10-K, which is available on our website at https://investors.ppdi.com or the SEC’s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Source

Recent Articles

TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a prespecified exploratory analysis of the positive...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.